Wei Xiao

Wei Xiao

Auto-generated profile, based on publicly available information

Wei Xiao

Department of Laboratory Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, 510317, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510317, China; Guangdong Pharmaceutical University, Guangzhou, 510006, China; Guangdong Medical University, Zhanjiang, Guangdong, 524023, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in Journal of Materials Chemistry C
Verified
Journal Article
Closed access
PDF file
PZPeili Zhao
Peili Zhao
YCYaofei Chen
Yaofei Chen
YCYu Chen
Yu Chen
SHShiqi Hu
Shiqi Hu
HCHui Chen
Hui Chen
ZCZhe Chen
Zhe Chen
Herein, MoS2 nanoflowers were deposited on a plasmonic interface for a sensitivity-enhanced immunoassay by increasing the amount of the loaded antibodies.

20 August 2019 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
SYShuange Yao
Shuange Yao
WXWei Xiao
Wei Xiao
HCHui Chen
Hui Chen
YTYong Tang
Yong Tang
QSQifang Song
Qifang Song
NDNing Deng
Ning Deng
Detection of the biomarkers human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) is an important parameter for ovarian cancer diagnosis and follow-up. For this reason, our study aimed to develop an immunological detection method for simultaneous detection of multiple ovarian cancer biomarkers based on a dual-signal system. The dual-signal system consists of quantum dot nanospheres (QDNBs) and fluorescent nanoparticles (FNPs) that emit different wavelengths of fluorescence under different excitation light. The HE4 and CA125 detection antibodies were conjugated with FNPs and QDNBs to form signal complexes, which produce a signal proportional to the concentration of HE4 and CA125. This dual-signal immunoassay was applied to human serum samples to detect HE4 and CA125 levels and compare them using an electrochemiluminescence (ECL) assay. The linear range of the assay was determined to be 1.25–20 ng mL−1 for HE4, and 9.4–200 U mL−1 for CA125. Comparison of 25 human serum samples subjected to the ECL assay resulted in impressive correlation coefficients of 0.91 and 0.96 for HE4 and CA125, respectively. A quantitative method for detecting HE4 and CA125 was successfully established. Preliminary clinical sample analysis showed that the dual-signal immunoassay has a strong clinical value in the screening and diagnosis of ovarian cancer.

13 May 2019 in ACS Sensors
Verified
Journal Article
Closed access
WXWei Xiao
Wei Xiao
MXMeng Xiao
Meng Xiao
SYShuange Yao
Shuange Yao
HCHongmin Cheng
Hongmin Cheng
HSHaicong Shen
Haicong Shen
YTYong Tang
Yong Tang

11 June 2025 in Talanta
Verified
Journal Article
Closed access
WXWei Xiao
Wei Xiao
FXFengjuan Xu
Fengjuan Xu
CLCong Lin
Cong Lin
QZQian Zhao
Qian Zhao
YHYuanyuan Han
Yuanyuan Han
DCDong-Lin Cao
Dong-Lin Cao

7 January 2026 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
QZQian Zhao
Qian Zhao
SSShibo Shang
Shibo Shang
MLMaorui Lin
Maorui Lin
YHYuanyuan Han
Yuanyuan Han
JDJiting Deng
Jiting Deng
DCDonglin Cao
Donglin Cao